Aclaris Therapeutics (ACRS) Tops Q4 EPS by 17c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Aclaris Therapeutis (ACRS): Eskata and Pipeline Should Drive Shares Higher - Cantor Fitzgerald
March 12, 2018 11:19 AM EDTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $50 price target on Aclaris Therapeutis (NASDAQ: ACRS), saying Eskata and the pipeline should drive share higher.
Chen commented, "Post a solid quarter of execution, and ahead of important catalysts for the company, we... More
Aclaris Therapeutics (ACRS) Announces U.S. Patent for JAK Inhibitor to Treat Hair Loss
March 9, 2018 8:02 AM ESTAclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,895,301, which is directed to methods related to the use and administration of a certain janus kinase (JAK) inhibitor for treating hair loss disorders.
U.S. Patent No. 9,895,301 covers the use of tofacitinib for inducing hair growth and for treating hair loss disorders such as alopecia areata and androgenetic alopecia (AGA), otherwise known as male/female pattern hair loss. Additional issued claims pertain to methods of... More
